Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.

6 ), there were highly significant reductions in all namilumab treatment arms versus placebo from week 2.

also in 132,142 other papers

At week 12, the proportion of subjects with ≥ 40% reduction in pain was 44.0%, 39.1%, and 30.8% for namilumab 20, 80, and 150 mg, respectively, versus 20.0% for placebo, but it did not reach statistical significance ( p values namilumab versus placebo were 0.075, 0.151, and 0.381 for 20 mg, 80 mg, and 150 mg, respectively).

also in 111,027 other papers